文献速递肝病消化道肿瘤与早癌

miR-107调控KIF23控制小鼠和人肝细胞癌复制性肿瘤细胞适应性

Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2024-09-01

研究利用三种致病机制不同的小鼠肝癌模型转录组数据,发现miR-107表达显著降低,其靶基因Kif23高表达与肝癌不良预后相关;过表达miR-107或抑制Kif23可减少细胞增殖、存活和运动,并在体内抑制c-Myc-NRAS诱导的侵袭性肝癌发生。

要点

  • miR-107在多种病因小鼠肝癌模型及人肝癌队列中表达显著降低。
  • KIF23高表达与肝癌不良预后相关,是预后标志物。
  • 过表达miR-107或抑制Kif23可抑制小鼠和人肝癌细胞增殖、存活和运动。

核心结论

  • 破坏miR-107/Kif23轴在体外抑制肝癌细胞增殖,在体内阻止癌基因诱导的肝癌发生,为人类肝细胞癌治疗提供新潜在途径。

研究设计与样本

  • 研究分析三种致病机制不同的小鼠肝癌模型的基因组miRNA和mRNA表达数据,并用TCGA、GEO数据库及组织微阵列验证小鼠靶点及其对人肝癌预后的影响,最后在水动力尾静脉注射临床前肝癌模型体内测试靶点功能。

主要发现

  • miR-107在多种病因小鼠肝肿瘤模型及人肝癌队列中表达显著降低。
  • 过表达miR-107或抑制其新靶点驱动蛋白家族成员23(Kif23)通过干扰胞质分裂显著降低小鼠和人肝癌细胞增殖,并控制其存活和运动。
  • 人KIF23表达是肝癌预后标志物,高表达与不良预后相关。
  • 水动力尾静脉注射携带pre-miR-107或抗Kif23 shRNA的载体抑制了小鼠高度侵袭性c-Myc-NRAS诱导的肝癌发展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In hepatocellular carcinoma (HCC), successful translation of experimental targets identified in mouse models to human patients has proven challenging. In this study, we used a comprehensive transcriptomic approach in mice to identify novel potential targets for therapeutic intervention in humans. METHODS: We analyzed combined genome-wide miRNA and mRNA expression data in three pathogenically distinct mouse models of liver cancer. Effects of target genes on hepatoma cell fitness were evaluated by proliferation, survival and motility assays. TCGA and GEO databases, in combination with tissue microarrays, were used to validate the mouse targets and their impact on human HCC prognosis. Finally, the functional effects of the identified targets on tumorigenesis and tumor therapy were tested in hydrodynamic tail vein injection-based preclinical HCC models in vivo. RESULTS: The expression of miR-107 was found to be significantly reduced in mouse models of liver tumors of various etiologies and in cohorts of humans with HCC. Overexpression of miR-107 or inhibition of its novel target kinesin family member 23 (Kif23) significantly reduced proliferation by interfering with cytokinesis, thereby controlling survival and motility of mouse and human hepatoma cells. In humans, KIF23 expression was found to be a prognostic marker in liver cancer, with high expression associated with poor prognosis. Hydrodynamic tail vein injection of vectors carrying either pre-miR-107 or anti-Kif23 shRNA inhibited the development of highly aggressive c-Myc-NRAS-induced liver cancers in mice. CONCLUSIONS: Disruption of the miR-107/Kif23 axis inhibited hepatoma cell proliferation in vitro and prevented oncogene-induced liver cancer development in vivo, offering a novel potential avenue for the treatment of HCC in humans. IMPACT AND IMPLICATIONS: Our study revealed the central role of the miR-107/KIF23 axis in controlling tumor cell fitness and hepatocellular carcinoma progression. The results demonstrate that the overexpression of miR-107 or silencing of its target, KIF23, markedly suppresses the proliferation, survival, and motility of human and mouse hepatoma cells. In this work, we demonstrate that the disruption of miR-107/Kif23 signaling effectively protects mice from an aggressive form of oncogene-induced liver cancer in vivo, implying that targeting miR-107/KIF23 might be a novel therapeutic approach for hepatocellular carcinoma in humans.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Castoldi M, Roy S, Angendohr C, et al. Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma. J Hepatol. 2024. PMID: 40235270. doi:10.1016/j.jhep.2024.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。